Erectile dysfunction (ED) and cardiovascular disease (CVD) share risk factors and frequently coexist, with endothelial dysfunction believed to be the pathophysiologic link. ED is common, affecting more than 70% of men with known CVD. In addition, clinical studies have demonstrated that ED in men with no known CVD often precedes a CVD event by 2-5 years. ED severity has been correlated with increasing plaque burden in patients with coronary artery disease. ED is an independent marker of increased CVD risk including all-cause and especially CVD mortality, particularly in men aged 30-60 years. Thus, ED identifies a window of opportunity for CVD risk mitigation. We recommend that a thorough history, physical exam (including visceral adiposity), assessment of ED severity and duration and evaluation including fasting plasma glucose, lipids, resting electrocardiogram, family history, lifestyle factors, serum creatinine (estimated glomerular filtration rate) and albumin:creatinine ratio, and determination of the presence or absence of the metabolic syndrome be performed to characterise cardiovascular risk in all men with ED. Assessment of testosterone levels should also be considered and biomarkers may help to further quantify risk, even though their roles in development of CVD have not been firmly established. Finally, we recommend that a question about ED be included in assessment of CVD risk in all men and be added to CVD risk assessment guidelines.

Journal of Men's HealthVol. 7, No. 3 ISMH Congress 2010 AbstractsIs there a change for International Prostate Symptom Scores (IPPS) following 3-piece penile prosthesis insertion? Results from a prospective seriesISMH World Congress 2010 Abstract 152A.J. Bella, D. Nienow, R. Shamloul, and A. NehraA.J. BellaSearch for more papers by this author, D. NienowSearch for more papers by this author, R. ShamloulSearch for more papers by this author, and A. NehraSearch for more papers by this authorPublished Online:18 Nov 2013https://doi.org/10.1016/j.jomh.2010.09.153AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View article"Is there a change for International Prostate Symptom Scores (IPPS) following 3-piece penile prosthesis insertion? Results from a prospective series." Journal of Men's Health, 7(3), pp. 329–330FiguresReferencesRelatedDetails Volume 7Issue 3Oct 2010 InformationWPMH GmbHTo cite this article:A.J. Bella, D. Nienow, R. Shamloul, and A. Nehra.Is there a change for International Prostate Symptom Scores (IPPS) following 3-piece penile prosthesis insertion? Results from a prospective series.Journal of Men's Health.Oct 2010.329-330.http://doi.org/10.1016/j.jomh.2010.09.153Published in Volume: 7 Issue 3: November 18, 2013PDF download

Journal of Men's HealthVol. 7, No. 3 ISMH Congress 2010 AbstractsResearch Funding by the National Institutes of Health: Does Gender Matter?ISMH World Congress 2010 Abstract 182R. Pinkhasov, J. Jhaveri, S. Ghannam, J. Kashanian, A. Nehra, M. Miner, and Ridwan ShabsighR. PinkhasovSearch for more papers by this author, J. JhaveriSearch for more papers by this author, S. GhannamSearch for more papers by this author, J. KashanianSearch for more papers by this author, A. NehraSearch for more papers by this author, M. MinerSearch for more papers by this author, and Ridwan ShabsighSearch for more papers by this authorPublished Online:18 Nov 2013https://doi.org/10.1016/j.jomh.2010.09.183AboutSectionsView articleView Full TextPDF/EPUB ToolsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View article"Research Funding by the National Institutes of Health: Does Gender Matter?." Journal of Men's Health, 7(3), p. 339FiguresReferencesRelatedDetails Volume 7Issue 3Oct 2010 InformationWPMH GmbHTo cite this article:R. Pinkhasov, J. Jhaveri, S. Ghannam, J. Kashanian, A. Nehra, M. Miner, and Ridwan Shabsigh.Research Funding by the National Institutes of Health: Does Gender Matter?.Journal of Men's Health.Oct 2010.339-339.http://doi.org/10.1016/j.jomh.2010.09.183Published in Volume: 7 Issue 3: November 18, 2013PDF download

The human hypothalamic–pituitary–testicular axis maintains testosterone production and spermatogenesis through an intricate feedforward and feedback system involving the intermittent exchange of neurohormonal signals. The chief components of this ensemble are hypothalamic gonadotropin-releasing hormone, pituitary luteinizing hormone, and testicular sex steroids (testosterone and estradiol). Epidemiological data and clinical experiments jointly indicate that healthy older men have lower bioavailable and free testosterone concentrations, higher sex hormone-binding globulin concentrations, and decreased daily testosterone secretion rates, compared with young individuals. Aging also disrupts quantifiable synchrony among sleep stage, the secretion of luteinizing hormone, testosterone, prolactin, and follicle-stimulating hormone, and the oscillations in nocturnal penile tumescence, denoting erosion of coordinate central neurohormonal outflow. How age affects spermatogenesis in healthy populations is not known. This article summarizes how aging in men is marked by multisite regulatory failure within the gonadal axis.

Childhood obesity rates have shown a rising trend in the past years, becoming a public health challenge and threat. The aim of this study was to examine the association between extracurricular activities and weight status, among children. A survey was performed in 1728 primary school Greek students, during school years 2014–2016. Dietary and lifestyle habits, such as engagement in a variety of extracurricular activities were evaluated. The KIDMED Score was used to assess the level of adherence to the Mediterranean diet. Children’s Body Mass Index (BMI) was calculated and classified as normal, overweight, or obese, according to the International Obesity Task Force (IOTF) classification. The prevalence of overweight was 21.7% and obesity 5.0%, with a greater proportion of overweight/obese boys than girls (32.4% vs. 23.3%; p < 0.001). Increased engagement on extracurricular activities, such as watching TV, reading out-of-school material and reduced participation in sports activities were associated with a higher likelihood of overweight/obesity (p < 0.05). Extracurricular physical activities can be promoted within the family environment and incentives or obstacles should be considered and addressed.

This paper provides a systematic review of the literature about prostate cancer risk associated with testosterone therapy for hypogonadism. A comprehensive search of MEDLINE, EMBASE and other resources was conducted to identify articles that highlight occurrences of prostate cancer in men receiving testosterone therapy for hypogonadism treatment. Articles that met study inclusion criteria were assessed for causality between testosterone treatment and prostate cancer, increased prostate-specific antigen or abnormal digital rectal examination findings. Of 197 articles relating to testosterone therapy, 44 met inclusion criteria: 11 placebo-controlled, randomized studies; 29 non-placebo-controlled studies of men with no prostate cancer history; and 4 studies of hypogonadal men with history of prostate cancer. Of studies that met inclusion criteria, none demonstrated that testosterone therapy for hypogonadism increased prostate cancer risk or increased Gleason grade of cancer detected in treated vs untreated men. Testosterone therapy did not have a consistent effect on prostate-specific antigen levels.

At our institution, a 64-channel CT urography (CTU) CT scanner was recently introduced. Sixty four-channel CT systems have been recognized to deliver improved spatial resolution over previous multichannel CT systems. Our objectives were to correlate the 64 multidetector CT urographic interpretations with cystoscopy and urine cytologies in 42 consecutive patients with a history of hematuria and/or prior history of TCC.

The majority of masses found within the scrotal sac are usually within the testes and neoplastic. However, a subset of these tumors arise from paratesticular tissues and are extratesticular. Paratesticular tumors, although infrequent, are associated with a high incidence of malignancy.

Recent studies have highlighted the relation between erectile dysfunction (ED) and cardiovascular disease. In particular, the role of endothelial dysfunction and nitric oxide in ED and atherosclerotic disease has been elucidated. Given the large number of men receiving medical treatment for ED, concerns regarding the risk for sexual activity triggering acute cardiovascular events and potential risks of adverse or unanticipated drug interactions need to be addressed. A risk stratification algorithm was developed by the First Princeton Consensus Panel to evaluate the degree of cardiovascular risk associated with sexual activity for men with varying degrees of cardiovascular disease. Patients were assigned to 3 categories: low, intermediate (including those requiring further evaluation), and high risk. This consensus study from the Second Princeton Consensus Conference corroborates and clarifies the algorithm and emphasizes the importance of risk factor evaluation and management for all patients with ED. The panel reviewed recent safety and drug interaction data for 3 phosphodiesterase (PDE)-5 inhibitors (sildenafil, tadalafil, vardenafil), with emphasis on the safety of these agents in men with ED and concomitant cardiovascular disease. Increasing evidence supports the role of lifestyle intervention in ED, specifically weight loss and increased physical activity, particularly in patients with ED and concomitant cardiovascular disease. Special management recommendations for patients taking PDE-5 inhibitors who present at the emergency department and other emergency medical situations are described. Finally, further research on the role of PDE-5 inhibition in treating patients with other medical or cardiovascular disorders is recommended.

Introduction Skin grafting of penile defects is difficult because of the flexibility of the underlying recipient bed. This leads to disruption of the vascular ingrowth into the skin graft and compromises the results of the reconstruction. Technical Considerations We successfully used a vacuum-assisted closure dressing with an incorporated wooden framework to secure penile skin grafts in place during the early postoperative period. Conclusions A vacuum-assisted closure dressing can be used successfully to secure large and circumferential skin grafts, as well as skin grafts on concealed penises.

A Phase I, double-blind, randomized, crossover study in healthy males (N=106) was conducted between March 21, 2004, and May 17, 2004, to determine the magnitude and duration of the hemodynamic interaction of avanafil (a phosphodiesterase type-5 inhibitor for treating males with erectile dysfunction) when coadministered with glyceryl trinitrate (NTG) compared with sildenafil and placebo. Subjects received avanafil (200 mg), sildenafil (100 mg), and placebo (on separate days) via the oral route followed by NTG (0.4 mg) 12, 8, 4, 1, or 0.5 hours post-dose via the sublingual route. Blood pressure (BP) and heart rate (HR) were assessed at defined intervals. Throughout the study (after administration of the study drug, and including the period after NTG administration), the effects of avanafil and sildenafil on BP and HR were significantly greatest overall, at the shortest (0.5-hour) time interval compared with placebo. By the 8- and 12-hour time intervals, no significant difference in BP or HR was observed for avanafil (8 and 12 hours) or sildenafil (12 hours) (p>0.05, compared with placebo). Compared with avanafil, sildenafil had a significantly greater effect when dosed 0.5 hours before NTG on standing HR (p=0.05); 1 hour before NTG on standing systolic blood pressure (SBP) (p<0.05), sitting SBP (p=0.01) and standing HR (p<0.01); and 12 hours before NTG on standing SBP (p=0.05). Throughout the study, symptomatic hypotension adverse events occurred in 27%, 29%, and 12%, and clinically significant reductions in standing SBP (≥30 mmHg) occurred in 15%, 29%, and 12% of subjects dosed with avanafil, sildenafil, and placebo, respectively (overall treatment differences: p<0.01 and p<0.05, respectively). These data show that avanafil and sildenafil have no significant effect on BP and HR if administered to healthy males ≥8 hours (avanafil) or ≥12 hours (sildenafil) before a sublingual dose of NTG. However, results may differ in populations with known vascular disease, especially those using other concurrent pharmacotherapy. These findings may be of interest to clinicians who treat patients with erectile dysfunction and who also have a cardiovascular condition. Of note, the applicability of these results in such patients may be limited because the enrollment comprised healthy, normal subjects.

In the first of these mini–reviews the selection of therapy for the maintenance of sexual function in patients with BPH is outlined, along with an explanation of how altered regulation of neurotransmitters, especially noradrenaline, may underlie the syndrome of LUTS and sexual dysfunction. Other mini‐reviews outline the current status of robotic surgery to treat renal and adrenal disorders, and its future applications, and the potential use of the nitric oxide/cGMP pathway as a potential target to treat BOO associated with benign prostatic enlargement. Finally, the capacity to be creative in academic departments is extolled as a core property of academicians, and its surfacing described as having the potential to revitalize individuals and departments.

You have accessJournal of UrologyPodium, Monday, May 23, 2005, 3:30 - 5:30 pm1 Apr 2005935: Single-Blind, Multi-Center, Placebo-Controlled, Parallel Study to Assess the Safety and Efficacy of Intralesional Interferon Alpha-2b in the Nonsurgical Treatment of Peyronie's Disease Muammer Kendirci, Richard Matern, Sepehr Nowfar, Dennis Venable, Stanton Honig, Andrew R. McCullough, Lawrence S. Hakim, Ajay Nehra, Jon L. Pryor, Lance E. Templeton, and Wayne J.G. Hellstrom Muammer KendirciMuammer Kendirci More articles by this author , Richard MaternRichard Matern More articles by this author , Sepehr NowfarSepehr Nowfar More articles by this author , Dennis VenableDennis Venable More articles by this author , Stanton HonigStanton Honig More articles by this author , Andrew R. McCulloughAndrew R. McCullough More articles by this author , Lawrence S. HakimLawrence S. Hakim More articles by this author , Ajay NehraAjay Nehra More articles by this author , Jon L. PryorJon L. Pryor More articles by this author , Lance E. TempletonLance E. Templeton More articles by this author , and Wayne J.G. HellstromWayne J.G. Hellstrom More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(18)35091-2AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "935: Single-Blind, Multi-Center, Placebo-Controlled, Parallel Study to Assess the Safety and Efficacy of Intralesional Interferon Alpha-2b in the Nonsurgical Treatment of Peyronie's Disease." The Journal of Urology, 173(4S), p. 253 © 2016 by American Urological AssociationFiguresReferencesRelatedDetails Volume 173Issue 4SApril 2005Page: 253 Advertisement Copyright & Permissions© 2016 by American Urological AssociationMetricsAuthor Information Muammer Kendirci More articles by this author Richard Matern More articles by this author Sepehr Nowfar More articles by this author Dennis Venable More articles by this author Stanton Honig More articles by this author Andrew R. McCullough More articles by this author Lawrence S. Hakim More articles by this author Ajay Nehra More articles by this author Jon L. Pryor More articles by this author Lance E. Templeton More articles by this author Wayne J.G. Hellstrom More articles by this author Expand All Advertisement PDF downloadLoading ...